<DOC>
	<DOCNO>NCT01713842</DOCNO>
	<brief_summary>Phase 1 : Patients treat infusion Tocilizumab ( TCZ ) 3 month . Clinical evaluation perform use PMR-AS . The PMR-AS compute sum 5 variable multiply 0.1 weighting purpose : PMR-AS ( activity scale = AS ) = C reactive protein ( CRP ) ( mg/dl ) + patient scale ( VASp ) ( 0-10 scale ) + physician scale ( VASph ) ( 0-10 scale ) + morning stiffness ( MST ) [ min ] ×0.1 ) + elevation upper limb ( EUL ) ( 0-3 scale ) . At end phase 1 , patient stop TCZ enter phase 2 week 12 . Phase 2 : All patient include phase 2 treat glucocorticoid ( GC ) 3 month . Two arm possible accord PMR-AS . Either classical GC treatment ( 0.3mg/kg ) , either low dose group GC ( 0.15mg/kg ) .</brief_summary>
	<brief_title>Tocilizumab Effect iN pOlymyalgia Rheumatica</brief_title>
	<detailed_description />
	<mesh_term>Polymyalgia Rheumatica</mesh_term>
	<mesh_term>Giant Cell Arteritis</mesh_term>
	<criteria>Age 50 year 75 year include PMRAS &gt; 10 PMR accord Chuang criterion Evolving since less 12 month Without Horton disease Able understand accept study Agree sign inform consent form Without GC , least 1 month stop since 7 day inclusion . Stable dose Nonsteroidal antiinflammatory since 4 week inclusion . Birth control study 6 month Disagree participate Unable understand study Participation study 3 month inclusion Treated GC 0.3mg/kg/d past 7 day Less 50 year old 75 year old Uncontrolled dyslipidemia , high blood pressure cardiovascular disease Histories important allergy Historically positive test test positive screening HIV1 antibody , hepatitis B surface antigen , hepatitis C antibody . Abnormal screen blood test : leukocyte count le 3.5 × 109 cells/L , neutrophil count le 2 × 109 cells/L , hemoglobin level less 85 g/L , platelet count le 100 × 109 cells/L , hepatic aminotransferase alkaline phosphatase level great 3 time upper limit normal Other inflammatory rheumatic disease connective disease Clinical evidence significant unstable uncontrolled acute chronic disease due PMR ( eg . Cardiovascular , pulmonary , hematologic , gastrointestinal , hepatic , renal , neurological , malignancy infectious disease ) Current drug alcohol abuse Patients treat immunosuppressive agent past 4 week Live/attenuated vaccine past 4 week Clinical symptom giant cell arteritis History infection infestation past 3 month Active tuberculosis Planned surgical procedure History malignant neoplasm within last 5 year , except adequately treated cancer skin ( basal squamous cell ) History current tumoral hematological disease Severe allergic anaphylactic reaction one TCZ component Pregnant woman study six month end study Breast feeding mother Dysthyroidia Unstable treatment statin past 3 month Parkinson disease Fibromyalgia Peripheric arthritis Articular chondrocalcinosis hydorxyapatites rhumatisms</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Tocilizumab</keyword>
	<keyword>Polymyalgia Rheumatica</keyword>
	<keyword>Glucocorticotherapy</keyword>
	<keyword>PMR-AS</keyword>
</DOC>